NCT01527838View on ClinicalTrials.gov

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions

Non-Hodgkin's Lymphoma (NHL)Hodgkin's DiseaseChronic Lymphocytic Leukemia (CLL)Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)

Interventions

BIOLOGICAL

Single FT1050 treated UCB unit

Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood

Trial Locations (3)

43210

Ohio State Univeristy Comprehensive Cancer Center, Columbus

02214

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program, Boston

Sponsors

Lead Sponsor

Fate Therapeutics

All Listed Sponsors

lead

Fate Therapeutics

INDUSTRY

NCT01527838 - Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | Biotech Hunter | Biotech Hunter